Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied...

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many
Dissatisfied with Current Treatment Options

New Long-Acting Injection in Development

WASHINGTON and CHADDS FORD, Pa., June 10 /PRNewswire/ -- About 63 percent of
men who suffered from low testosterone saw two or more doctors before the
condition was diagnosed, and once treated, nearly 30 percent of men said they
stopped taking their medicine, according to results of a survey released
today.

Results of the poll of more than 100 men who had been diagnosed with and
treated for low testosterone, were released at the annual meeting of the
Endocrine Society. The most frequent symptoms respondents reported were lack
of energy (87 percent), decreased concentration (83 percent), loss of sex
drive (82 percent) and the inability to get or maintain an erection (80
percent).

An estimated 13.9 million American men have low testosterone, also known as
hypogonadism, yet only 9 percent of men are currently being treated with
testosterone replacement therapy. The condition takes a significant toll on
men's lives. Among men polled, 97 percent said low testosterone had a
somewhat or very negative impact on the sexual aspect of their lives, and 90
percent said it adversely affected their self esteem.

"Low testosterone levels may have a marked impact on a man's sense of well
being," said Raymond Rosen, Ph.D., Chief Scientist of the New England Research
Institutes in Watertown, Mass. Among men polled, 61 percent said they were
generally unsatisfied with their lives before being treated.

Low testosterone is associated with a broad range of physical, psychological
and sexual symptoms including decreased energy and mood, fatigue, loss of
muscle mass, depressed libido and erectile dysfunction. In addition, low
testosterone has been associated with other serious medical conditions
including diabetes, cardiovascular disease and metabolic syndrome.

"These symptoms are vague and non-specific, which may account for the apparent
under-diagnosis of low testosterone," Dr. Martin M. Miner, MD , Co-Director of
the Men's Health Center Miriam Hospital and Clinical, Providence, R.I. and
Associate Clinical Professor of Family Medicine Warren Alpert School of
Medicine of Brown University, said. According to the survey, 36 percent of
respondents saw two physicians before being diagnosed while 19 percent saw
three doctors and 9 percent saw four. "This clearly speaks to the need for
greater awareness among physicians of the condition and also for more
patient-friendly treatments, since most men with this hormone deficiency will
need to stay on treatment for life," Dr. Miner said.

Current treatment options include transdermal patches and gels that must be
applied to the skin on a daily basis. Patients using gels must take care to
prevent any transfer of testosterone to partners or children, as they have
been associated with inappropriate genitalia enlargement and aggression in
children. Short-acting testosterone injections are another, less popular
treatment option that must be administered every two to four weeks.

"Despite the benefits of treatment, staying on therapy can be a problem for
some men," Dr. Rosen said. According to the survey, 64 percent of men had
used two or more testosterone replacement medicines, and 28 percent of men
reported that they had stopped taking their medication at some point.

New long-acting injections that only need to be administered five times in the
first year following the initial injection and every 10 weeks thereafter are
in development and may offer patients a convenient new option for treatment.
A majority of men polled said five shots in a year would be an improvement
over their current therapies.

Although testosterone levels decline with age, hypogonadism is not a natural
consequence of the aging process. "Men with clinically diagnosed hypogonadism
do not need to 'tolerate' the symptoms of low testosterone," Dr. Miner said.
"There may be important physical benefits to treatment, such as increased
muscle mass and a reduced risk for osteoporosis. We are only beginning to
explore/appreciate the link between low testosterone and more serious medical
conditions such as diabetes and cardiovascular disease."

The internet survey was conducted by Forrest W. Anderson during March and
April and was sponsored by Endo Pharmaceuticals Inc., which is developing the
first and only long-acting injectable testosterone replacement treatment in
the U.S. Testosterone undecanoate currently is pending U.S. Food and Drug
Administration approval. Testosterone undecanoate was first approved in
Europe in 2003 and is now marketed as Nebido in more than 80 countries by
Bayer Schering Pharma AG.

ABOUT HYPOGONADISM

Hypogonadism, also known as low testosterone, is a common yet largely
under-recognized and under-treated condition that affects an estimated 13.8
million men in the United States. Only 9 percent of American men with low
testosterone are currently being treated with testosterone replacement
therapy.

Low testosterone is associated with a broad range of physical, psychological
and sexual symptoms including decreased energy and mood, fatigue, loss of
muscle mass, decreased libido and erectile dysfunction. In addition, low
testosterone is associated with other serious medical conditions including
diabetes, cardiovascular disease and metabolic syndrome.

ABOUT ENDO

Endo Pharmaceuticals (Nasdaq: ENDP) is a specialty pharmaceutical company
engaged in the research, development, sale and marketing of branded and
generic prescription pharmaceuticals used to treat and manage pain, overactive
bladder, prostate cancer and the early onset of puberty in children, or
central precocious puberty (CPP). Its products include LIDODERM(R), a topical
patch to relieve the pain of postherpetic neuralgia; Percocet(R) and
Percodan(R) tablets for the relief of moderate-to-moderately severe pain;
FROVA(R) tablets for the acute treatment of migraine attacks with or without
aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute
pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the
relief of moderate-to-severe pain in patients requiring continuous,
around-the-clock opioid treatment for an extended period of time; and
Voltaren(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the
relief of the pain of osteoarthritis of joints amenable to topical treatment
such as those of the hands and the knees. Voltaren(R) Gel is owned and
licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of
overactive bladder, VANTAS(R) for the palliative treatment of advanced
prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty
in children. The company markets its branded pharmaceutical products to
physicians in pain management, neurology, surgery, oncology, endocrinology and
primary care. More information, including this and past press releases of
Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding, among other
things, the acquisition of Indevus, the company's financial position, results
of operations, market position, product development and business strategy, as
well as estimates of future net sales, future expenses, future net income and
future earnings per share. Statements including words such as "believes,"
"expects," "anticipates," "intends," "estimates," "plan," "will," "may,"
"intend," "guidance" or similar expressions are forward-looking statements.
Because these statements reflect our current views, expectations and beliefs
concerning future events, these forward-looking statements involve risks and
uncertainties. Investors should note that many factors could affect our future
financial results and could cause our actual results to differ materially from
those expressed in forward-looking statements contained in this press release.
These factors include, but are not limited to: the possibility that the
transaction will not be completed, or if completed, not completed on a timely
basis; the possibility that the acquisition of Indevus is not complementary to
Endo; the inherent uncertainty of the timing and success of, and expense
associated with, research, development, regulatory approval and
commercialization of our products and pipeline products; competition in our
industry, including for branded and generic products, and in connection with
our acquisition of rights to assets, including intellectual property;
government regulation of the pharmaceutical industry; our dependence on a
small number of products and on outside manufacturers for the manufacture of
our products; our dependence on third parties to supply raw materials and to
provide services for certain core aspects of our business; new regulatory
action or lawsuits relating to our use of controlled substances in many of our
core products; our exposure to product liability claims and product recalls
and the possibility that we may not be able to adequately insure ourselves;
our ability to protect our proprietary technology; our ability to successfully
implement our in-licensing and acquisition strategy; the availability of
third-party reimbursement for our products; the outcome of any pending or
future litigation or claims by the government; our dependence on sales to a
limited number of large pharmacy chains and wholesale drug distributors for a
large portion of our total net sales; a determination by a regulatory agency
that we are engaging in inappropriate sales or marketing activities, including
promoting the "off-label" use of our products; the loss of branded product
exclusivity periods and related intellectual property; and exposure to
securities that are subject to market risk including auction-rate securities
the market for which is currently illiquid; and other risks and uncertainties,
including those detailed from time to time in our periodic reports filed with
the Securities and Exchange Commission, including our current reports on Form
8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K,
particularly the discussion under the caption "Item 1A, RISK FACTORS" in our
annual report on Form 10-K for the year ended December 31, 2008, which was
filed with the Securities and Exchange Commission on March 2, 2009. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, we think
could cause our actual results to differ materially from expected and
historical results. We assume no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

SOURCE Endo Pharmaceuticals

Media/Investors, Blaine Davis, +1-610-459-7158, or Media, Kevin Wiggins,
+1-610-459-7281, both of Endo Pharmaceuticals